MapLight TherapeuticsMPLT +3.09%14 EBIT per Share is $-4.82 as of Mar. 2026. GuruFocus rates MPLT with a GF Score™ of 14/100. The stock has 4 warning signs investors should review. Among 1,178 Biotechnology companies, MapLight Therapeutics ranks worse than 99.15% on this metric.
MapLight Therapeutics's EBIT per Share for the
three
months ended in Mar. 2026 was $-1.43.
Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $-4.82.
During the past 3 years, the average EBIT per Share Growth Rate was -153.60% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for MapLight Therapeutics's EBIT per Share or its related term are showing as below:
MPLT'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -153.6 Med: -153.6 Max: -153.6
Current: -153.6
During the past 4 years, the highest 3-Year average EBIT per Share Growth Rate of MapLight Therapeutics was -153.60% per year. The lowest was -153.60% per year. And the median was -153.60% per year.
MPLT's 3-Year EBIT Growth Rate is ranked worse than 99.15% of 1178
companies
in the Biotechnology industry
Industry Median: 15.55
vs MPLT: -153.60
MapLight Therapeutics (NAS:MPLT) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
MapLight Therapeutics EBIT per Share Related Terms
MapLight Therapeutics EBIT per Share Historical Data
* Premium members only.
The historical data trend for MapLight Therapeutics's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-4.82
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MapLight Therapeutics (MPLT) has a EBIT per Share of $-4.82 as of Mar. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on MapLight Therapeutics and its competitors. According to the industry distribution chart, MapLight Therapeutics ranks #1168 out of 1178 companies in the Biotechnology industry, placing it in the top 99.2%.
Is MapLight Therapeutics' EBIT per Share too high?
MapLight Therapeutics' current EBIT per Share is $-4.82. Based on the distribution chart, MapLight Therapeutics ranks #1168 out of 1178 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, MapLight Therapeutics has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does MapLight Therapeutics' EBIT per Share compare to COAG and CAPR?
According to the Biotechnology industry distribution chart, MapLight Therapeutics ranks #1168 out of 1178 companies for EBIT per Share. This places MapLight Therapeutics in the lower half of its industry. The industry median EBIT per Share is 15.55. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Biotechnology company?
The median EBIT per Share among Biotechnology companies is 15.55, based on 1,178 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on MapLight Therapeutics and its competitors. For the Biotechnology industry, the median EBIT per Share is 15.55 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. MapLight Therapeutics's current EBIT per Share is $-4.82. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MapLight Therapeutics stock overvalued right now?
MapLight Therapeutics (MPLT) has a current EBIT per Share of $-4.82. The current EBIT per Share is $-4.82. MapLight Therapeutics' overall GF Score™ is 14/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For MapLight Therapeutics (MPLT), the current EBIT per Share is $-4.82 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
MapLight Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system disorders. Its discovery platform identifies neural circuits causally linked to disease and targets them for therapeutic modulation, aiming to improve efficacy, safety, tolerability, and ease of use. The company was founded by leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies. Its product candidate, ML-007C-MA, is a fixed-dose combination of an M1/M4 muscarinic agonist and a peripherally acting anticholinergic, being developed for schizophrenia and Alzheimer's disease psychosis, designed to activate central receptors while mitigating peripheral side effects.
14GF Score
Get the complete analysis for MPLT
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MPLT has been successfully added to your 
